Q-omics provides the consensus-scored PHBP20 profile across patient tissues and cancer cell-line models. PHBP20 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PHBP20 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, PHBP20 RNA expression shows 9,594 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where PHBP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP20 survival associations across molecular data types. PHBP20 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP20 RNA expression–survival associations across cancer types. High PHBP20 expression shows unfavorable associations in KIRC, UVM, UCS, STAD, HNSC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PHBP20 RNA expression.
This table summarizes PHBP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP20 shows higher tumor expression in COAD, LIHC and LUAD. The COAD box plot shows higher PHBP20 RNA expression in tumor versus normal tissue (log2 FC = +0.315, t-test p < 0.001).
This table shows molecular features associated with PHBP20 in patient tissues and cancer cell lines. In patient samples, PHBP20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
